APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurotransmitter Inhibitor Peptides

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurotransmitter Inhibitor Peptides Market Analysis and Forecast 2026-2032

13 August 2026213 pages

Choose your research edition.

Industry ResearchNeurotransmitter Inhibitor Peptides Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurotransmitter Inhibitor Peptides Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Neurotransmitter Inhibitor Peptides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurotransmitter Inhibitor Peptides Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurotransmitter Inhibitor Peptides Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Neurotransmitter Inhibitor Peptides market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Neurotransmitter Inhibitor Peptides's global sales reached XX (t) with a value of US$ XX Million, marking an change of XX% compared to the previous year. This performance has positioned Lubrizol (Lipotec) as the global sales leader, a title it has maintained for several consecutive years. Notably, Lubrizol (Lipotec)'s performance in primary markets is also remarkable. In the Chinese market, sales were XX (t), a change of XX% from the previous year. In Europe, sales were XX (t), showing a year-on-year of XX%. In the US, sales were XX (t), a year-on-year change of XX%.

The major global manufacturers in the Neurotransmitter Inhibitor Peptides market include Lubrizol (Lipotec), dsm-firmenich, LipoTrue, Spec-Chem Industry, GenScript, Active Peptide Company, Uniproma Chemical, BOC Sciences (AAPEP) and GfN Selco, etc. In 2025, the top three vendors accounted for approximately % of the revenue.

Read the full market overview

In terms of production side, this report researches the Neurotransmitter Inhibitor Peptides production, growth rate, market share by manufacturers and by region (region level and country level), from 2021 to 2026, and forecast to 2032.

In terms of consumption side, this report focuses on the sales of Neurotransmitter Inhibitor Peptides by region (region level and country level), by Company, by Type and by Application. from 2021 to 2026 and forecast to 2032.

This report presents an overview of global market for Neurotransmitter Inhibitor Peptides, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurotransmitter Inhibitor Peptides, also provides the consumption of main regions and countries. Of the upcoming market potential for Neurotransmitter Inhibitor Peptides, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurotransmitter Inhibitor Peptides sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurotransmitter Inhibitor Peptides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neurotransmitter Inhibitor Peptides sales, projected growth trends, production technology, application and end-user industry.

Neurotransmitter Inhibitor Peptides Segment by Company

Lubrizol (Lipotec)

dsm-firmenich

LipoTrue

Spec-Chem Industry

GenScript

Active Peptide Company

Uniproma Chemical

BOC Sciences (AAPEP)

GfN Selco

COSROMA

Gene-Biocon

ChinaPeptides (QYAOBIO)

Pengting Peptide

RS Synthesis

Shenzhen JYMed Technology Co., Ltd.

Nanjing Peptide Biotech

AAPPTec

Tianji Bio-pharmaceutical

Zhejiang Peptites Biotech

Guangzhou Tongjun Pharmaceutical Technology

Hantide Biomedical Group

Hangzhou Go Top Biotech

Neurotransmitter Inhibitor Peptides Segment by Type

SNARE-Complex Modulating Peptides

SNAP-25 Mimicking Peptides

Others

Neurotransmitter Inhibitor Peptides Segment by Application

Eye Care Products

Facial Serums

Face Creams and Lotions

Other

Neurotransmitter Inhibitor Peptides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurotransmitter Inhibitor Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurotransmitter Inhibitor Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurotransmitter Inhibitor Peptides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Neurotransmitter Inhibitor Peptides production/output of global and key producers (regions/countries). It provides a quantitative analysis of the production, and development potential of each producer in the next six years.

Chapter 4: Sales (consumption), revenue of Neurotransmitter Inhibitor Peptides in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 5: Detailed analysis of Neurotransmitter Inhibitor Peptides manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurotransmitter Inhibitor Peptides sales, revenue, price, gross margin, and recent development, etc.

Chapter 9: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 10: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 11: China by type, by application, sales, and revenue for each segment.

Chapter 12: Asia (Excluding China) by type, by application and by region, sales, and revenue for each segment.

Chapter 13: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 14: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 15: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurotransmitter Inhibitor Peptides Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. SNARE-Complex Modulating Peptides Major Manufacturers Table 3. SNAP-25 Mimicking Peptides Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Neurotransmitter Inhibitor Peptides Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Eye Care Products Major Manufacturers Table 7. Facial Serums Major Manufacturers Table 8. Face Creams and Lotions Major Manufacturers Table 9. Other Major Manufacturers Table 10. Neurotransmitter Inhibitor Peptides Industry Trends Table 11. Neurotransmitter Inhibitor Peptides Industry Drivers Table 12. Neurotransmitter Inhibitor Peptides Industry Opportunities and Challenges Table 13. Neurotransmitter Inhibitor Peptides Industry Restraints Table 14. Global Neurotransmitter Inhibitor Peptides Production Growth Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (t) Table 15. Global Neurotransmitter Inhibitor Peptides Production by Region (2021-2026) & (t) Table 16. Global Neurotransmitter Inhibitor Peptides Production by Region (2027-2032) & (t) Table 17. Global Neurotransmitter Inhibitor Peptides Production Market Share by Region (2021-2026) Table 18. Global Neurotransmitter Inhibitor Peptides Production Market Share by Region (2027-2032) Table 19. Global Neurotransmitter Inhibitor Peptides Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Neurotransmitter Inhibitor Peptides Revenue by Region (2021-2026) & (US$ Million) Table 21. Global Neurotransmitter Inhibitor Peptides Revenue by Region (2027-2032) & (US$ Million) Table 22. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Region (2021-2026) Table 23. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Region (2027-2032) Table 24. Global Neurotransmitter Inhibitor Peptides Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (t) Table 25. Global Neurotransmitter Inhibitor Peptides Sales by Region (2021-2026) & (t) Table 26. Global Neurotransmitter Inhibitor Peptides Sales by Region (2027-2032) & (t) Table 27. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region (2021-2026) Table 28. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region (2027-2032) Table 29. Global Neurotransmitter Inhibitor Peptides Revenue by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Manufacturers (2021-2026) Table 31. Global Neurotransmitter Inhibitor Peptides Sales by Manufacturers (US$ Million) & (2021-2026) Table 32. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Manufacturers (2021-2026) Table 33. Global Neurotransmitter Inhibitor Peptides Sales Price (USD/t) of Manufacturers (2021-2026) Table 34. Global Neurotransmitter Inhibitor Peptides Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 35. Global Neurotransmitter Inhibitor Peptides Key Manufacturers Manufacturing Sites & Headquarters Table 36. Global Neurotransmitter Inhibitor Peptides Manufacturers, Product Type & Application Table 37. Global Neurotransmitter Inhibitor Peptides Manufacturers Commercialization Time Table 38. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 39. Global Neurotransmitter Inhibitor Peptides by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 40. Global Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2026) & (US$ Million) Table 41. Global Neurotransmitter Inhibitor Peptides Revenue by Type (2027-2032) & (US$ Million) Table 42. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Type (2021-2026) Table 43. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Type (2027-2032) Table 44. Global Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 45. Global Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 46. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Type (2021-2026) Table 47. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Type (2027-2032) Table 48. Global Neurotransmitter Inhibitor Peptides Price by Type (2021-2026) & (USD/t) Table 49. Global Neurotransmitter Inhibitor Peptides Price by Type (2027-2032) & (USD/t) Table 50. Global Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Neurotransmitter Inhibitor Peptides Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Application (2021-2026) Table 53. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Application (2027-2032) Table 54. Global Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 55. Global Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 56. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Application (2021-2026) Table 57. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Application (2027-2032) Table 58. Global Neurotransmitter Inhibitor Peptides Price by Application (2021-2026) & (USD/t) Table 59. Global Neurotransmitter Inhibitor Peptides Price by Application (2027-2032) & (USD/t) Table 60. Lubrizol (Lipotec) Company Information Table 61. Lubrizol (Lipotec) Business Overview Table 62. Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 63. Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Product Portfolio Table 64. Lubrizol (Lipotec) Recent Development Table 65. dsm-firmenich Company Information Table 66. dsm-firmenich Business Overview Table 67. dsm-firmenich Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 68. dsm-firmenich Neurotransmitter Inhibitor Peptides Product Portfolio Table 69. dsm-firmenich Recent Development Table 70. LipoTrue Company Information Table 71. LipoTrue Business Overview Table 72. LipoTrue Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 73. LipoTrue Neurotransmitter Inhibitor Peptides Product Portfolio Table 74. LipoTrue Recent Development Table 75. Spec-Chem Industry Company Information Table 76. Spec-Chem Industry Business Overview Table 77. Spec-Chem Industry Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 78. Spec-Chem Industry Neurotransmitter Inhibitor Peptides Product Portfolio Table 79. Spec-Chem Industry Recent Development Table 80. GenScript Company Information Table 81. GenScript Business Overview Table 82. GenScript Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 83. GenScript Neurotransmitter Inhibitor Peptides Product Portfolio Table 84. GenScript Recent Development Table 85. Active Peptide Company Company Information Table 86. Active Peptide Company Business Overview Table 87. Active Peptide Company Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 88. Active Peptide Company Neurotransmitter Inhibitor Peptides Product Portfolio Table 89. Active Peptide Company Recent Development Table 90. Uniproma Chemical Company Information Table 91. Uniproma Chemical Business Overview Table 92. Uniproma Chemical Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 93. Uniproma Chemical Neurotransmitter Inhibitor Peptides Product Portfolio Table 94. Uniproma Chemical Recent Development Table 95. BOC Sciences (AAPEP) Company Information Table 96. BOC Sciences (AAPEP) Business Overview Table 97. BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 98. BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Product Portfolio Table 99. BOC Sciences (AAPEP) Recent Development Table 100. GfN Selco Company Information Table 101. GfN Selco Business Overview Table 102. GfN Selco Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 103. GfN Selco Neurotransmitter Inhibitor Peptides Product Portfolio Table 104. GfN Selco Recent Development Table 105. COSROMA Company Information Table 106. COSROMA Business Overview Table 107. COSROMA Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 108. COSROMA Neurotransmitter Inhibitor Peptides Product Portfolio Table 109. COSROMA Recent Development Table 110. Gene-Biocon Company Information Table 111. Gene-Biocon Business Overview Table 112. Gene-Biocon Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 113. Gene-Biocon Neurotransmitter Inhibitor Peptides Product Portfolio Table 114. Gene-Biocon Recent Development Table 115. ChinaPeptides (QYAOBIO) Company Information Table 116. ChinaPeptides (QYAOBIO) Business Overview Table 117. ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 118. ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Product Portfolio Table 119. ChinaPeptides (QYAOBIO) Recent Development Table 120. Pengting Peptide Company Information Table 121. Pengting Peptide Business Overview Table 122. Pengting Peptide Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 123. Pengting Peptide Neurotransmitter Inhibitor Peptides Product Portfolio Table 124. Pengting Peptide Recent Development Table 125. RS Synthesis Company Information Table 126. RS Synthesis Business Overview Table 127. RS Synthesis Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 128. RS Synthesis Neurotransmitter Inhibitor Peptides Product Portfolio Table 129. RS Synthesis Recent Development Table 130. Shenzhen JYMed Technology Co., Ltd. Company Information Table 131. Shenzhen JYMed Technology Co., Ltd. Business Overview Table 132. Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 133. Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Product Portfolio Table 134. Shenzhen JYMed Technology Co., Ltd. Recent Development Table 135. Nanjing Peptide Biotech Company Information Table 136. Nanjing Peptide Biotech Business Overview Table 137. Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 138. Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 139. Nanjing Peptide Biotech Recent Development Table 140. AAPPTec Company Information Table 141. AAPPTec Business Overview Table 142. AAPPTec Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 143. AAPPTec Neurotransmitter Inhibitor Peptides Product Portfolio Table 144. AAPPTec Recent Development Table 145. Tianji Bio-pharmaceutical Company Information Table 146. Tianji Bio-pharmaceutical Business Overview Table 147. Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 148. Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Product Portfolio Table 149. Tianji Bio-pharmaceutical Recent Development Table 150. Zhejiang Peptites Biotech Company Information Table 151. Zhejiang Peptites Biotech Business Overview Table 152. Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 153. Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 154. Zhejiang Peptites Biotech Recent Development Table 155. Guangzhou Tongjun Pharmaceutical Technology Company Information Table 156. Guangzhou Tongjun Pharmaceutical Technology Business Overview Table 157. Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 158. Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Product Portfolio Table 159. Guangzhou Tongjun Pharmaceutical Technology Recent Development Table 160. Hantide Biomedical Group Company Information Table 161. Hantide Biomedical Group Business Overview Table 162. Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 163. Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Product Portfolio Table 164. Hantide Biomedical Group Recent Development Table 165. Hangzhou Go Top Biotech Company Information Table 166. Hangzhou Go Top Biotech Business Overview Table 167. Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 168. Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 169. Hangzhou Go Top Biotech Recent Development Table 170. North America Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2026) & (US$ Million) Table 171. North America Neurotransmitter Inhibitor Peptides Revenue by Type (2027-2032) & (US$ Million) Table 172. North America Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 173. North America Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 174. North America Neurotransmitter Inhibitor Peptides Sales Price by Type (2021-2026) & (USD/t) Table 175. North America Neurotransmitter Inhibitor Peptides Sales Price by Type (2027-2032) & (USD/t) Table 176. North America Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2026) & (US$ Million) Table 177. North America Neurotransmitter Inhibitor Peptides Revenue by Application (2027-2032) & (US$ Million) Table 178. North America Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 179. North America Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 180. North America Neurotransmitter Inhibitor Peptides Sales Price by Application (2021-2026) & (USD/t) Table 181. North America Neurotransmitter Inhibitor Peptides Sales Price by Application (2027-2032) & (USD/t) Table 182. North America Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. North America Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. North America Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. North America Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032) & (t) Table 186. North America Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 187. North America Neurotransmitter Inhibitor Peptides Sales by Country (2027-2032) & (t) Table 188. North America Neurotransmitter Inhibitor Peptides Sales Price by Country (2021-2026) & (USD/t) Table 189. North America Neurotransmitter Inhibitor Peptides Sales Price by Country (2027-2032) & (USD/t) Table 190. United States Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 191. Canada Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 192. Mexico Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 193. Europe Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2026) & (US$ Million) Table 194. Europe Neurotransmitter Inhibitor Peptides Revenue by Type (2027-2032) & (US$ Million) Table 195. Europe Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 196. Europe Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 197. Europe Neurotransmitter Inhibitor Peptides Sales Price by Type (2021-2026) & (USD/t) Table 198. Europe Neurotransmitter Inhibitor Peptides Sales Price by Type (2027-2032) & (USD/t) Table 199. Europe Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2026) & (US$ Million) Table 200. Europe Neurotransmitter Inhibitor Peptides Revenue by Application (2027-2032) & (US$ Million) Table 201. Europe Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 202. Europe Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 203. Europe Neurotransmitter Inhibitor Peptides Sales Price by Application (2021-2026) & (USD/t) Table 204. Europe Neurotransmitter Inhibitor Peptides Sales Price by Application (2027-2032) & (USD/t) Table 205. Europe Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. Europe Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. Europe Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. Europe Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032) & (t) Table 209. Europe Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 210. Europe Neurotransmitter Inhibitor Peptides Sales by Country (2027-2032) & (t) Table 211. Europe Neurotransmitter Inhibitor Peptides Sales Price by Country (2021-2026) & (USD/t) Table 212. Europe Neurotransmitter Inhibitor Peptides Sales Price by Country (2027-2032) & (USD/t) Table 213. Germany Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 214. France Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 215. U.K. Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 216. Italy Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 217. Russia Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 218. Spain Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 219. Netherlands Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 220. Switzerland Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 221. Sweden Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 222. Poland Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 223. China Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2026) & (US$ Million) Table 224. China Neurotransmitter Inhibitor Peptides Revenue by Type (2027-2032) & (US$ Million) Table 225. China Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 226. China Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 227. China Neurotransmitter Inhibitor Peptides Sales Price by Type (2021-2026) & (USD/t) Table 228. China Neurotransmitter Inhibitor Peptides Sales Price by Type (2027-2032) & (USD/t) Table 229. China Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2026) & (US$ Million) Table 230. China Neurotransmitter Inhibitor Peptides Revenue by Application (2027-2032) & (US$ Million) Table 231. China Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 232. China Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 233. China Neurotransmitter Inhibitor Peptides Sales Price by Application (2021-2026) & (USD/t) Table 234. China Neurotransmitter Inhibitor Peptides Sales Price by Application (2027-2032) & (USD/t) Table 235. Asia Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2026) & (US$ Million) Table 236. Asia Neurotransmitter Inhibitor Peptides Revenue by Type (2027-2032) & (US$ Million) Table 237. Asia Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 238. Asia Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 239. Asia Neurotransmitter Inhibitor Peptides Sales Price by Type (2021-2026) & (USD/t) Table 240. Asia Neurotransmitter Inhibitor Peptides Sales Price by Type (2027-2032) & (USD/t) Table 241. Asia Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2026) & (US$ Million) Table 242. Asia Neurotransmitter Inhibitor Peptides Revenue by Application (2027-2032) & (US$ Million) Table 243. Asia Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 244. Asia Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 245. Asia Neurotransmitter Inhibitor Peptides Sales Price by Application (2021-2026) & (USD/t) Table 246. Asia Neurotransmitter Inhibitor Peptides Sales Price by Application (2027-2032) & (USD/t) Table 247. Asia Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 248. Asia Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 249. Asia Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 250. Asia Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032) & (t) Table 251. Asia Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 252. Asia Neurotransmitter Inhibitor Peptides Sales by Country (2027-2032) & (t) Table 253. Asia Neurotransmitter Inhibitor Peptides Sales Price by Country (2021-2026) & (USD/t) Table 254. Asia Neurotransmitter Inhibitor Peptides Sales Price by Country (2027-2032) & (USD/t) Table 255. Japan Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 256. South Korea Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 257. India Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 258. Australia Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 259. Taiwan Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 260. Southeast Asia Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 261. SAMEA Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2026) & (US$ Million) Table 262. SAMEA Neurotransmitter Inhibitor Peptides Revenue by Type (2027-2032) & (US$ Million) Table 263. SAMEA Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 264. SAMEA Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 265. SAMEA Neurotransmitter Inhibitor Peptides Sales Price by Type (2021-2026) & (USD/t) Table 266. SAMEA Neurotransmitter Inhibitor Peptides Sales Price by Type (2027-2032) & (USD/t) Table 267. SAMEA Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2026) & (US$ Million) Table 268. SAMEA Neurotransmitter Inhibitor Peptides Revenue by Application (2027-2032) & (US$ Million) Table 269. SAMEA Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 270. SAMEA Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 271. SAMEA Neurotransmitter Inhibitor Peptides Sales Price by Application (2021-2026) & (USD/t) Table 272. SAMEA Neurotransmitter Inhibitor Peptides Sales Price by Application (2027-2032) & (USD/t) Table 273. SAMEA Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 274. SAMEA Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 275. SAMEA Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 276. SAMEA Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032) & (t) Table 277. SAMEA Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 278. SAMEA Neurotransmitter Inhibitor Peptides Sales by Country (2027-2032) & (t) Table 279. SAMEA Neurotransmitter Inhibitor Peptides Sales Price by Country (2021-2026) & (USD/t) Table 280. SAMEA Neurotransmitter Inhibitor Peptides Sales Price by Country (2027-2032) & (USD/t) Table 281. Brazil Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 282. Argentina Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 283. Chile Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 284. Colombia Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 285. Peru Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 286. Saudi Arabia Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 287. Israel Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 288. UAE Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 289. Turkey Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 290. Iran Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 291. Egypt Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Table 292. Key Raw Materials Table 293. Raw Materials Key Suppliers Table 294. Neurotransmitter Inhibitor Peptides Distributors List Table 295. Neurotransmitter Inhibitor Peptides Customers List Table 296. Research Programs/Design for This Report Table 297. Authors List of This Report Table 298. Secondary Sources Table 299. Primary Sources List of Figures Figure 1. Neurotransmitter Inhibitor Peptides Product Image Figure 2. Global Neurotransmitter Inhibitor Peptides Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurotransmitter Inhibitor Peptides Market Size Share 2021 VS 2025 VS 2032 Figure . SNARE-Complex Modulating Peptides Image Figure 1. SNAP-25 Mimicking Peptides Image Figure 2. Others Image Figure 3. Global Neurotransmitter Inhibitor Peptides Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Neurotransmitter Inhibitor Peptides Market Size Share 2021 VS 2025 VS 2032 Figure 5. Eye Care Products Image Figure 6. Facial Serums Image Figure 7. Face Creams and Lotions Image Figure 8. Other Image Figure 9. Global Neurotransmitter Inhibitor Peptides Capacity, Capacity Utilization (2021-2032) & (t) Figure 10. Global Neurotransmitter Inhibitor Peptides Production by Region: 2021 VS 2025 VS 2032 (t) Figure 11. Global Neurotransmitter Inhibitor Peptides Production Market Share by Region: 2025 Versus 2032 Figure 12. Global Neurotransmitter Inhibitor Peptides Production Market Share by Region (2021-2032) Figure 13. North America Neurotransmitter Inhibitor Peptides Production Growth Rate (2021-2032) & (t) Figure 14. Europe Neurotransmitter Inhibitor Peptides Production Growth Rate (2021-2032) & (t) Figure 15. China Neurotransmitter Inhibitor Peptides Production Growth Rate (2021-2032) & (t) Figure 16. Japan Neurotransmitter Inhibitor Peptides Production Growth Rate (2021-2032) & (t) Figure 17. Global Neurotransmitter Inhibitor Peptides Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Neurotransmitter Inhibitor Peptides Revenue (2021-2032) & (US$ Million) Figure 19. Global Neurotransmitter Inhibitor Peptides Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Region (2021-2032) Figure 22. Global Neurotransmitter Inhibitor Peptides Sales (2021-2032) & (t) Figure 23. Global Neurotransmitter Inhibitor Peptides Sales by Region: 2021 VS 2025 VS 2032 (t) Figure 24. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region (2021-2032) Figure 25. North America Neurotransmitter Inhibitor Peptides Sales YoY (2021-2032) & (t) Figure 26. Europe Neurotransmitter Inhibitor Peptides Sales YoY (2021-2032) & (t) Figure 27. China Neurotransmitter Inhibitor Peptides Sales YoY (2021-2032) & (t) Figure 28. Asia (Excluding China) Neurotransmitter Inhibitor Peptides Sales YoY (2021-2032) & (t) Figure 29. South America, Middle East and Africa Neurotransmitter Inhibitor Peptides Sales YoY (2021-2032) & (t) Figure 30. Global Neurotransmitter Inhibitor Peptides Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global Neurotransmitter Inhibitor Peptides Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Type (2021-2032) Figure 34. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Type (2021-2032) Figure 35. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Application (2021-2032) Figure 36. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Application (2021-2032) Figure 37. North America Neurotransmitter Inhibitor Peptides Revenue Share by Type (2021-2032) Figure 38. North America Neurotransmitter Inhibitor Peptides Sales Share by Type (2021-2032) Figure 39. North America Neurotransmitter Inhibitor Peptides Revenue Share by Application (2021-2032) Figure 40. North America Neurotransmitter Inhibitor Peptides Sales Share by Application (2021-2032) Figure 41. North America Neurotransmitter Inhibitor Peptides Revenue Share by Country (2021-2032) Figure 42. North America Neurotransmitter Inhibitor Peptides Sales Share by Country (2021-2032) Figure 43. Europe Neurotransmitter Inhibitor Peptides Revenue Share by Type (2021-2032) Figure 44. Europe Neurotransmitter Inhibitor Peptides Sales Share by Type (2021-2032) Figure 45. Europe Neurotransmitter Inhibitor Peptides Revenue Share by Application (2021-2032) Figure 46. Europe Neurotransmitter Inhibitor Peptides Sales Share by Application (2021-2032) Figure 47. Europe Neurotransmitter Inhibitor Peptides Revenue Share by Country (2021-2032) Figure 48. Europe Neurotransmitter Inhibitor Peptides Sales Share by Country (2021-2032) Figure 49. China Neurotransmitter Inhibitor Peptides Revenue Share by Type (2021-2032) Figure 50. China Neurotransmitter Inhibitor Peptides Sales Share by Type (2021-2032) Figure 51. China Neurotransmitter Inhibitor Peptides Revenue Share by Application (2021-2032) Figure 52. China Neurotransmitter Inhibitor Peptides Sales Share by Application (2021-2032) Figure 53. Asia Neurotransmitter Inhibitor Peptides Revenue Share by Type (2021-2032) Figure 54. Asia Neurotransmitter Inhibitor Peptides Sales Share by Type (2021-2032) Figure 55

Scope & coverage.

Types
  • SNARE-Complex Modulating Peptides
  • SNAP-25 Mimicking Peptides
  • Others
Applications
  • Eye Care Products
  • Facial Serums
  • Face Creams and Lotions
  • Other
Companies covered
  • Lubrizol (Lipotec)
  • dsm-firmenich
  • LipoTrue
  • Spec-Chem Industry
  • GenScript
  • Active Peptide Company
  • Uniproma Chemical
  • BOC Sciences (AAPEP)
  • GfN Selco
  • COSROMA
  • Gene-Biocon
  • ChinaPeptides (QYAOBIO)
  • Pengting Peptide
  • RS Synthesis
  • Shenzhen JYMed Technology Co., Ltd.
  • Nanjing Peptide Biotech
  • AAPPTec
  • Tianji Bio-pharmaceutical
  • Zhejiang Peptites Biotech
  • Guangzhou Tongjun Pharmaceutical Technology
  • Hantide Biomedical Group
  • Hangzhou Go Top Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurotransmitter Inhibitor Peptides Market by Type
  3. 1.2.1 Global Neurotransmitter Inhibitor Peptides Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 SNARE-Complex Modulating Peptides
  5. 1.2.3 SNAP-25 Mimicking Peptides
  6. 1.2.4 Others
  7. 1.3 Neurotransmitter Inhibitor Peptides Market by Application
  8. 1.3.1 Global Neurotransmitter Inhibitor Peptides Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Eye Care Products
  10. 1.3.3 Facial Serums
  11. 1.3.4 Face Creams and Lotions
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neurotransmitter Inhibitor Peptides Market Dynamics
  1. 2.1 Neurotransmitter Inhibitor Peptides Industry Trends
  2. 2.2 Neurotransmitter Inhibitor Peptides Industry Drivers
  3. 2.3 Neurotransmitter Inhibitor Peptides Industry Opportunities and Challenges
  4. 2.4 Neurotransmitter Inhibitor Peptides Industry Restraints
3 Global Neurotransmitter Inhibitor Peptides Production Overview
  1. 3.1 Global Neurotransmitter Inhibitor Peptides Production Capacity (2021-2032)
  2. 3.2 Global Neurotransmitter Inhibitor Peptides Production by Region: 2021 VS 2025 VS 2032
  3. 3.3 Global Neurotransmitter Inhibitor Peptides Production by Region
  4. 3.3.1 Global Neurotransmitter Inhibitor Peptides Production by Region (2021-2026)
  5. 3.3.2 Global Neurotransmitter Inhibitor Peptides Production by Region (2027-2032)
  6. 3.3.3 Global Neurotransmitter Inhibitor Peptides Production Market Share by Region (2021-2032)
  7. 3.4 North America
  8. 3.5 Europe
  9. 3.6 China
  10. 3.7 Japan
4 Global Market Growth Prospects
  1. 4.1 Global Neurotransmitter Inhibitor Peptides Revenue Estimates and Forecasts (2021-2032)
  2. 4.2 Global Neurotransmitter Inhibitor Peptides Revenue by Region
  3. 4.2.1 Global Neurotransmitter Inhibitor Peptides Revenue by Region: 2021 VS 2025 VS 2032
  4. 4.2.2 Global Neurotransmitter Inhibitor Peptides Revenue by Region (2021-2026)
  5. 4.2.3 Global Neurotransmitter Inhibitor Peptides Revenue by Region (2027-2032)
  6. 4.2.4 Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Region (2021-2032)
  7. 4.3 Global Neurotransmitter Inhibitor Peptides Sales Estimates and Forecasts 2021-2032
  8. 4.4 Global Neurotransmitter Inhibitor Peptides Sales by Region
  9. 4.4.1 Global Neurotransmitter Inhibitor Peptides Sales by Region: 2021 VS 2025 VS 2032
  10. 4.4.2 Global Neurotransmitter Inhibitor Peptides Sales by Region (2021-2026)
  11. 4.4.3 Global Neurotransmitter Inhibitor Peptides Sales by Region (2027-2032)
  12. 4.4.4 Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region (2021-2032)
  13. 4.5 North America
  14. 4.6 Europe
  15. 4.7 China
  16. 4.8 Asia (Excluding China)
  17. 4.9 South America, Middle East and Africa
5 Market Competitive Landscape by Manufacturers
  1. 5.1 Global Neurotransmitter Inhibitor Peptides Revenue by Manufacturers
  2. 5.1.1 Global Neurotransmitter Inhibitor Peptides Revenue by Manufacturers (2021-2026)
  3. 5.1.2 Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Manufacturers (2021-2026)
  4. 5.1.3 Global Neurotransmitter Inhibitor Peptides Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 5.2 Global Neurotransmitter Inhibitor Peptides Sales by Manufacturers
  6. 5.2.1 Global Neurotransmitter Inhibitor Peptides Sales by Manufacturers (2021-2026)
  7. 5.2.2 Global Neurotransmitter Inhibitor Peptides Sales Market Share by Manufacturers (2021-2026)
  8. 5.2.3 Global Neurotransmitter Inhibitor Peptides Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 5.3 Global Neurotransmitter Inhibitor Peptides Sales Price by Manufacturers (2021-2026)
  10. 5.4 Global Neurotransmitter Inhibitor Peptides Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 5.5 Global Neurotransmitter Inhibitor Peptides Key Manufacturers Manufacturing Sites & Headquarters
  12. 5.6 Global Neurotransmitter Inhibitor Peptides Manufacturers, Product Type & Application
  13. 5.7 Global Neurotransmitter Inhibitor Peptides Manufacturers Commercialization Time
  14. 5.8 Market Competitive Analysis
  15. 5.8.1 Global Neurotransmitter Inhibitor Peptides Market CR5 and HHI
  16. 5.8.2 2025 Neurotransmitter Inhibitor Peptides Tier 1, Tier 2, and Tier 3
6 Neurotransmitter Inhibitor Peptides Market by Type
  1. 6.1 Global Neurotransmitter Inhibitor Peptides Revenue by Type
  2. 6.1.1 Global Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2032) & (US$ Million)
  3. 6.1.2 Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Type (2021-2032)
  4. 6.2 Global Neurotransmitter Inhibitor Peptides Sales by Type
  5. 6.2.1 Global Neurotransmitter Inhibitor Peptides Sales by Type (2021-2032) & (t)
  6. 6.2.2 Global Neurotransmitter Inhibitor Peptides Sales Market Share by Type (2021-2032)
  7. 6.3 Global Neurotransmitter Inhibitor Peptides Price by Type
7 Neurotransmitter Inhibitor Peptides Market by Application
  1. 7.1 Global Neurotransmitter Inhibitor Peptides Revenue by Application
  2. 7.1.1 Global Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2032) & (US$ Million)
  3. 7.1.2 Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Application (2021-2032)
  4. 7.2 Global Neurotransmitter Inhibitor Peptides Sales by Application
  5. 7.2.1 Global Neurotransmitter Inhibitor Peptides Sales by Application (2021-2032) & (t)
  6. 7.2.2 Global Neurotransmitter Inhibitor Peptides Sales Market Share by Application (2021-2032)
  7. 7.3 Global Neurotransmitter Inhibitor Peptides Price by Application
8 Company Profiles
  1. 8.1 Lubrizol (Lipotec)
  2. 8.1.1 Lubrizol (Lipotec) Company Information
  3. 8.1.2 Lubrizol (Lipotec) Business Overview
  4. 8.1.3 Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 8.1.4 Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Product Portfolio
  6. 8.1.5 Lubrizol (Lipotec) Recent Developments
  7. 8.2 dsm-firmenich
  8. 8.2.1 dsm-firmenich Company Information
  9. 8.2.2 dsm-firmenich Business Overview
  10. 8.2.3 dsm-firmenich Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 8.2.4 dsm-firmenich Neurotransmitter Inhibitor Peptides Product Portfolio
  12. 8.2.5 dsm-firmenich Recent Developments
  13. 8.3 LipoTrue
  14. 8.3.1 LipoTrue Company Information
  15. 8.3.2 LipoTrue Business Overview
  16. 8.3.3 LipoTrue Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 8.3.4 LipoTrue Neurotransmitter Inhibitor Peptides Product Portfolio
  18. 8.3.5 LipoTrue Recent Developments
  19. 8.4 Spec-Chem Industry
  20. 8.4.1 Spec-Chem Industry Company Information
  21. 8.4.2 Spec-Chem Industry Business Overview
  22. 8.4.3 Spec-Chem Industry Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 8.4.4 Spec-Chem Industry Neurotransmitter Inhibitor Peptides Product Portfolio
  24. 8.4.5 Spec-Chem Industry Recent Developments
  25. 8.5 GenScript
  26. 8.5.1 GenScript Company Information
  27. 8.5.2 GenScript Business Overview
  28. 8.5.3 GenScript Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 8.5.4 GenScript Neurotransmitter Inhibitor Peptides Product Portfolio
  30. 8.5.5 GenScript Recent Developments
  31. 8.6 Active Peptide Company
  32. 8.6.1 Active Peptide Company Company Information
  33. 8.6.2 Active Peptide Company Business Overview
  34. 8.6.3 Active Peptide Company Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 8.6.4 Active Peptide Company Neurotransmitter Inhibitor Peptides Product Portfolio
  36. 8.6.5 Active Peptide Company Recent Developments
  37. 8.7 Uniproma Chemical
  38. 8.7.1 Uniproma Chemical Company Information
  39. 8.7.2 Uniproma Chemical Business Overview
  40. 8.7.3 Uniproma Chemical Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 8.7.4 Uniproma Chemical Neurotransmitter Inhibitor Peptides Product Portfolio
  42. 8.7.5 Uniproma Chemical Recent Developments
  43. 8.8 BOC Sciences (AAPEP)
  44. 8.8.1 BOC Sciences (AAPEP) Company Information
  45. 8.8.2 BOC Sciences (AAPEP) Business Overview
  46. 8.8.3 BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 8.8.4 BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Product Portfolio
  48. 8.8.5 BOC Sciences (AAPEP) Recent Developments
  49. 8.9 GfN Selco
  50. 8.9.1 GfN Selco Company Information
  51. 8.9.2 GfN Selco Business Overview
  52. 8.9.3 GfN Selco Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 8.9.4 GfN Selco Neurotransmitter Inhibitor Peptides Product Portfolio
  54. 8.9.5 GfN Selco Recent Developments
  55. 8.10 COSROMA
  56. 8.10.1 COSROMA Company Information
  57. 8.10.2 COSROMA Business Overview
  58. 8.10.3 COSROMA Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 8.10.4 COSROMA Neurotransmitter Inhibitor Peptides Product Portfolio
  60. 8.10.5 COSROMA Recent Developments
  61. 8.11 Gene-Biocon
  62. 8.11.1 Gene-Biocon Company Information
  63. 8.11.2 Gene-Biocon Business Overview
  64. 8.11.3 Gene-Biocon Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 8.11.4 Gene-Biocon Neurotransmitter Inhibitor Peptides Product Portfolio
  66. 8.11.5 Gene-Biocon Recent Developments
  67. 8.12 ChinaPeptides (QYAOBIO)
  68. 8.12.1 ChinaPeptides (QYAOBIO) Company Information
  69. 8.12.2 ChinaPeptides (QYAOBIO) Business Overview
  70. 8.12.3 ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 8.12.4 ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Product Portfolio
  72. 8.12.5 ChinaPeptides (QYAOBIO) Recent Developments
  73. 8.13 Pengting Peptide
  74. 8.13.1 Pengting Peptide Company Information
  75. 8.13.2 Pengting Peptide Business Overview
  76. 8.13.3 Pengting Peptide Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 8.13.4 Pengting Peptide Neurotransmitter Inhibitor Peptides Product Portfolio
  78. 8.13.5 Pengting Peptide Recent Developments
  79. 8.14 RS Synthesis
  80. 8.14.1 RS Synthesis Company Information
  81. 8.14.2 RS Synthesis Business Overview
  82. 8.14.3 RS Synthesis Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 8.14.4 RS Synthesis Neurotransmitter Inhibitor Peptides Product Portfolio
  84. 8.14.5 RS Synthesis Recent Developments
  85. 8.15 Shenzhen JYMed Technology Co., Ltd.
  86. 8.15.1 Shenzhen JYMed Technology Co., Ltd. Company Information
  87. 8.15.2 Shenzhen JYMed Technology Co., Ltd. Business Overview
  88. 8.15.3 Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 8.15.4 Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Product Portfolio
  90. 8.15.5 Shenzhen JYMed Technology Co., Ltd. Recent Developments
  91. 8.16 Nanjing Peptide Biotech
  92. 8.16.1 Nanjing Peptide Biotech Company Information
  93. 8.16.2 Nanjing Peptide Biotech Business Overview
  94. 8.16.3 Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 8.16.4 Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  96. 8.16.5 Nanjing Peptide Biotech Recent Developments
  97. 8.17 AAPPTec
  98. 8.17.1 AAPPTec Company Information
  99. 8.17.2 AAPPTec Business Overview
  100. 8.17.3 AAPPTec Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 8.17.4 AAPPTec Neurotransmitter Inhibitor Peptides Product Portfolio
  102. 8.17.5 AAPPTec Recent Developments
  103. 8.18 Tianji Bio-pharmaceutical
  104. 8.18.1 Tianji Bio-pharmaceutical Company Information
  105. 8.18.2 Tianji Bio-pharmaceutical Business Overview
  106. 8.18.3 Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 8.18.4 Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Product Portfolio
  108. 8.18.5 Tianji Bio-pharmaceutical Recent Developments
  109. 8.19 Zhejiang Peptites Biotech
  110. 8.19.1 Zhejiang Peptites Biotech Company Information
  111. 8.19.2 Zhejiang Peptites Biotech Business Overview
  112. 8.19.3 Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 8.19.4 Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  114. 8.19.5 Zhejiang Peptites Biotech Recent Developments
  115. 8.20 Guangzhou Tongjun Pharmaceutical Technology
  116. 8.20.1 Guangzhou Tongjun Pharmaceutical Technology Company Information
  117. 8.20.2 Guangzhou Tongjun Pharmaceutical Technology Business Overview
  118. 8.20.3 Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 8.20.4 Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Product Portfolio
  120. 8.20.5 Guangzhou Tongjun Pharmaceutical Technology Recent Developments
  121. 8.21 Hantide Biomedical Group
  122. 8.21.1 Hantide Biomedical Group Company Information
  123. 8.21.2 Hantide Biomedical Group Business Overview
  124. 8.21.3 Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 8.21.4 Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Product Portfolio
  126. 8.21.5 Hantide Biomedical Group Recent Developments
  127. 8.22 Hangzhou Go Top Biotech
  128. 8.22.1 Hangzhou Go Top Biotech Company Information
  129. 8.22.2 Hangzhou Go Top Biotech Business Overview
  130. 8.22.3 Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 8.22.4 Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  132. 8.22.5 Hangzhou Go Top Biotech Recent Developments
9 North America
  1. 9.1 North America Neurotransmitter Inhibitor Peptides Market Size by Type
  2. 9.1.1 North America Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2032)
  3. 9.1.2 North America Neurotransmitter Inhibitor Peptides Sales by Type (2021-2032)
  4. 9.1.3 North America Neurotransmitter Inhibitor Peptides Price by Type (2021-2032)
  5. 9.2 North America Neurotransmitter Inhibitor Peptides Market Size by Application
  6. 9.2.1 North America Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2032)
  7. 9.2.2 North America Neurotransmitter Inhibitor Peptides Sales by Application (2021-2032)
  8. 9.2.3 North America Neurotransmitter Inhibitor Peptides Price by Application (2021-2032)
  9. 9.3 North America Neurotransmitter Inhibitor Peptides Market Size by Country
  10. 9.3.1 North America Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 North America Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 North America Neurotransmitter Inhibitor Peptides Price by Country (2021-2032)
  13. 9.3.4 United States
  14. 9.3.5 Canada
  15. 9.3.6 Mexico
10 Europe
  1. 10.1 Europe Neurotransmitter Inhibitor Peptides Market Size by Type
  2. 10.1.1 Europe Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2032)
  3. 10.1.2 Europe Neurotransmitter Inhibitor Peptides Sales by Type (2021-2032)
  4. 10.1.3 Europe Neurotransmitter Inhibitor Peptides Price by Type (2021-2032)
  5. 10.2 Europe Neurotransmitter Inhibitor Peptides Market Size by Application
  6. 10.2.1 Europe Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2032)
  7. 10.2.2 Europe Neurotransmitter Inhibitor Peptides Sales by Application (2021-2032)
  8. 10.2.3 Europe Neurotransmitter Inhibitor Peptides Price by Application (2021-2032)
  9. 10.3 Europe Neurotransmitter Inhibitor Peptides Market Size by Country
  10. 10.3.1 Europe Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 10.3.2 Europe Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032)
  12. 10.3.3 Europe Neurotransmitter Inhibitor Peptides Price by Country (2021-2032)
  13. 10.3.4 Germany
  14. 10.3.5 France
  15. 10.3.6 U.K.
  16. 10.3.7 Italy
  17. 10.3.8 Russia
  18. 10.3.9 Spain
  19. 10.3.10 Netherlands
  20. 10.3.11 Switzerland
  21. 10.3.12 Sweden
11 China
  1. 11.1 China Neurotransmitter Inhibitor Peptides Market Size by Type
  2. 11.1.1 China Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2032)
  3. 11.1.2 China Neurotransmitter Inhibitor Peptides Sales by Type (2021-2032)
  4. 11.1.3 China Neurotransmitter Inhibitor Peptides Price by Type (2021-2032)
  5. 11.2 China Neurotransmitter Inhibitor Peptides Market Size by Application
  6. 11.2.1 China Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2032)
  7. 11.2.2 China Neurotransmitter Inhibitor Peptides Sales by Application (2021-2032)
  8. 11.2.3 China Neurotransmitter Inhibitor Peptides Price by Application (2021-2032)
12 Asia (Excluding China)
  1. 12.1 Asia Neurotransmitter Inhibitor Peptides Market Size by Type
  2. 12.1.1 Asia Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2032)
  3. 12.1.2 Asia Neurotransmitter Inhibitor Peptides Sales by Type (2021-2032)
  4. 12.1.3 Asia Neurotransmitter Inhibitor Peptides Price by Type (2021-2032)
  5. 12.2 Asia Neurotransmitter Inhibitor Peptides Market Size by Application
  6. 12.2.1 Asia Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2032)
  7. 12.2.2 Asia Neurotransmitter Inhibitor Peptides Sales by Application (2021-2032)
  8. 12.2.3 Asia Neurotransmitter Inhibitor Peptides Price by Application (2021-2032)
  9. 12.3 Asia Neurotransmitter Inhibitor Peptides Market Size by Country
  10. 12.3.1 Asia Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 Asia Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 Asia Neurotransmitter Inhibitor Peptides Price by Country (2021-2032)
  13. 12.3.4 Japan
  14. 12.3.5 South Korea
  15. 12.3.6 India
  16. 12.3.7 Australia
  17. 12.3.8 Taiwan
  18. 12.3.9 Southeast Asia
13 South America, Middle East and Africa
  1. 13.1 SAMEA Neurotransmitter Inhibitor Peptides Market Size by Type
  2. 13.1.1 SAMEA Neurotransmitter Inhibitor Peptides Revenue by Type (2021-2032)
  3. 13.1.2 SAMEA Neurotransmitter Inhibitor Peptides Sales by Type (2021-2032)
  4. 13.1.3 SAMEA Neurotransmitter Inhibitor Peptides Price by Type (2021-2032)
  5. 13.2 SAMEA Neurotransmitter Inhibitor Peptides Market Size by Application
  6. 13.2.1 SAMEA Neurotransmitter Inhibitor Peptides Revenue by Application (2021-2032)
  7. 13.2.2 SAMEA Neurotransmitter Inhibitor Peptides Sales by Application (2021-2032)
  8. 13.2.3 SAMEA Neurotransmitter Inhibitor Peptides Price by Application (2021-2032)
  9. 13.3 SAMEA Neurotransmitter Inhibitor Peptides Market Size by Country
  10. 13.3.1 SAMEA Neurotransmitter Inhibitor Peptides Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 13.3.2 SAMEA Neurotransmitter Inhibitor Peptides Sales by Country (2021 VS 2025 VS 2032)
  12. 13.3.3 SAMEA Neurotransmitter Inhibitor Peptides Price by Country (2021-2032)
  13. 13.3.4 Brazil
  14. 13.3.5 Argentina
  15. 13.3.6 Chile
  16. 13.3.7 Colombia
  17. 13.3.8 Peru
  18. 13.3.9 Saudi Arabia
  19. 13.3.10 Israel
  20. 13.3.11 UAE
  21. 13.3.12 Turkey
  22. 13.3.13 Iran
  23. 13.3.14 Egypt
14 Value Chain and Sales Channels Analysis
  1. 14.1 Neurotransmitter Inhibitor Peptides Value Chain Analysis
  2. 14.1.1 Neurotransmitter Inhibitor Peptides Key Raw Materials
  3. 14.1.2 Raw Materials Key Suppliers
  4. 14.1.3 Manufacturing Cost Structure
  5. 14.1.4 Neurotransmitter Inhibitor Peptides Production Mode & Process
  6. 14.2 Neurotransmitter Inhibitor Peptides Sales Channels Analysis
  7. 14.2.1 Direct Comparison with Distribution Share
  8. 14.2.2 Neurotransmitter Inhibitor Peptides Distributors
  9. 14.2.3 Neurotransmitter Inhibitor Peptides Customers
15 Concluding Insights
    16 Appendix
    1. 16.1 Reasons for Doing This Study
    2. 16.2 Research Methodology
    3. 16.3 Research Process
    4. 16.4 Authors List of This Report
    5. 16.5 Data Source
    6. 16.5.1 Secondary Sources
    7. 16.5.2 Primary Sources
    8. 16.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst